(Q50971795)

26 March 2018

title

Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. (English)

1 reference

26 March 2018

1 reference

Sumiyoshi T

1

1 reference

26 March 2018

Hasegawa M

series ordinal

2

1 reference

26 March 2018

Jayathilake K

series ordinal

3

1 reference

26 March 2018

Meltzer HY

series ordinal

4

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 March 1997

1 reference

26 March 2018

published in

Biological Psychiatry

1 reference

26 March 2018

volume

41

1 reference

26 March 2018

issue

5

1 reference

26 March 2018

page(s)

560-566

1 reference

26 March 2018

Plasma homovanillic acid and performance on motor and cognitive tasks in community-dwelling elderly: MacArthur studies of successful aging.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

3,4-Dihydroxyphenylacetic acid and homovanillic acid in rat plasma: Possible indicators of central dopaminergic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Acute psychosis and plasma catecholamine metabolites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Sex differences in plasma homovanillic acid in acute psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Characteristics of patients with the highest plasma catecholamine metabolite levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

The neurodevelopmental basis of sex differences in schizophrenia1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma homovanillic acid and treatment response in a large group of schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Are there neurochemical indicators of risk for schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma homovanillic acid concentration and the severity of schizophrenic illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Dopamine in schizophrenia: a review and reconceptualization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

A diagnostic interview: the schedule for affective disorders and schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Clozapine response and plasma catecholamines and their metabolites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Epidemiology of puerperal psychoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Brain contribution to the haloperidol-induced increase in plasma homovanillic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Influence of dopamine agonists on plasma and brain levels of homovanillic acid.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Variations of monoamines and their metabolites in the human brain putamen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Regional homovanillic acid production in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Acute psychiatric admission related to the menstrual cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Studies of catecholamine metabolism in schizophrenia/psychosis--I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Studies of catecholamine metabolism in schizophrenia/psychosis--II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Effects of renal clearance on plasma concentrations of homovanillic acid. Methodologic cautions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

The role of estrogens in schizophrenia gender differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Plasma and CSF HVA before and after pharmacological treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Serum homovanillic acid levels in schizophrenic patients and normal control subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

Morning variations of plasma homovanillic acid in untreated schizophrenic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2896%2900099-6

10.1016/S0006-3223(96)00099-6

7 January 2021

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018